Karagiannis research group

Group Leader

Dr Tom Karagiannis

Research fellow
Dr Katherine Ververis

PhD students
Ms  Nadia Mazarakis
Ms Natalie Bonvino
Ms Sophia Chun

Masters students
Ms Julia Liang
Ms Neha Malik

Placement students
Ms Natalia Benetti
Mr Evan Kagarakis

E: tom.karagiannis@monash.edu
+61 3 9903 0491

Epigenomic Medicine

Key terms: Chromatin biology, epigenetics, DNA damage, nutrigenomics, diabetic foot, wound healing

Research goals

  1. Understand the role of dietary antioxidants and chromatin modifying compounds on the genome and epigenome in health and disease
  2. Develop predictive models of wound severity and potential for repair in the context of diabetic foot ulcers. This research direction also involves the development of new potential therapeutics.

The group

Feb 2017. L-R Ms Nadia Mazarakis (Doctoral student), Dr Tom Karagiannis (Lab head), Ms Neha Malik (Doctoral student, UMelb), Dr Katherine Ververis (Research Fellow), Mr Evan Kagarakis (Doctoral student, UMelb), Ms Julia Liang (Doctoral student), Ms Natalia Benetti (Masters student, RMIT).

Research Overview

Supported by McCord Research, the overall aim of the Epigenomic Medicine Laboratory is to investigate the effects of dietary antioxidants and chromatin modifying compounds on the genome and epigenome.  While nutrigenomics is relatively widely-investigated, the discipline of epigenomics represents the merged science of epigenetics and genomics.  The ultimate aim of this exciting field is to map and unravel the biological and biomedical significance of epigenetic phenomena.  The term epigenetics was introduced by the British scientist Conrad Waddington in the 1940s to incorporate all of the factors controlling gene expression and cell differentiation.  It was derived from the virtually redundant Aristotelian word of epigenesis, which was used by the Hellenic philosopher to describe his theory of gradual and progressive developmental changes. Today, epigenetics is typically defined as inherited phenotypic changes that are not due to changes in gene sequence.  However, an expanded approach may be to refer to epigenetics as an integrative view of the cellular and molecular mechanisms governing DNA metabolic processes including transcription, replication and repair.

In the Epigenomic Medicine Laboratory we investigate the underlying molecular mechanisms of action of dietary antioxidants and chromatin modifying compounds by investigating effects on the genome and epigenome, in various chronic progressive conditions including cardiovascular disease and cancer, with a particular emphasis in diabetes and diabetic foot ulcers. The laboratory utilises a range of conventional methodologies including mammalian cell culture and in vivo studies and specialises in biomedical imaging with expertise in the analysis of DNA damage and repair.  We routinely perform experiments at the Australian Synchrotron (>1000 hours of imaging to date) in collaboration with Infrared Microspectroscopy beamline scientists.  The laboratory undertakes genome-wide sequencing experiments using services at the Australian Genome Research Facility, and perform bioinformatics analysis using commercially available Partek Flow software. Further, we have very well established collaboration for performing molecular modelling and molecular dynamic simulation studies.

Projects and Opportunities

Project: Topical wound healing formulations in the context of diabetic complications
The cutaneous wound healing process involves three overlapping phases: acute inflammation, proliferation and remodelling. The process involves different cell types, including cells of the immune system, keratinocytes, fibroblasts and endothelial cells, as well as many different molecular factors and cytokines. Immediately following skin injury, damage signals, both mechanical and chemicals, are sent out from damaged cells and blood vessels to other cells in the area. Damaged cells activate stress pathways, and also leak molecular signals such as damage-associated molecular patterns which indicate stress to other cells. Chronic ulcers which display delayed wound healing are a common complication of diabetes. The aim of this project is to investigate the effects of combinations of dietary antioxidants and chromatin modifying compounds in various cell lines including human keratinocytes, endothelial cells and fibroblasts in models simulating diabetes. Further, we utilise EpiDerm full thickness 3D models of human skin containing keratinocytes, fibroblasts and intact basement membrane for ex-vivo evaluation of our topical formulations in response to high glucose-induced stress.

Project: Synchrotron- and focal plane array-based Fourier-transform infrared chemical mapping as a diagnostic tool in wound care
Aberrant wound healing, as observed in the presence of co-morbidities such as diabetes, represents a major clinical problem.  To improve wound care, a better understanding of the cellular and molecular details of healing processes is required.  The aim of this project is to utilise Synchrotron- and focal plane array (PFA)-based Fourier-transform infrared (FTIR) chemical mapping develop predictive models of initial damage and molecular details of the wound healing process.  Studies are combined with conventional histological and immunofluorescence analyses to identify potential diagnostic markers.

Project: Molecular mechanisms of action of dietary antioxidants and chromatin modifying compounds
Controlled equilibrium between histone acetylation and deacetylation is essential for normal cell growth and perturbations in histone acetylation status have been associated with various diseases.   Therefore, histone deacetylase inhibitors have emerged as a new class of cancer chemotherapeutics and are being investigated in inflammatory models including asthma and diabetes.  The aim of this project is to investigate cellular, genomic and epigenomic responses to a wide variety of dietary antioxidants and chromatin modifying compounds, with a particular interest in the isothiocyanate, L-sulphoraphane. We have well-established experimental models of human disease and utilize a wide  range of methodologies as described above.McCord Research

Current project funding

2012 – ongoing: McCord Research Holding Inc. Laboratory Fund  ($150,000 US per year) – Principal Investigator

Recent publications

Pubmed link [Karagiannis T]

  • Mah LJ, El-Osta A, Karagiannis TC. H2AX: a sensitive molecular marker of DNA damage and repair. Leukemia. 2010 Apr;24(4):679-86
  • Rodd AL, Ververis K, Sayakkarage D, Khan AW, Rafehi H, Ziemann M, Loveridge SJ, Lazarus R, Kerr C, Lockett T, El-Osta A, Karagiannis TC, Bennett LE. RNA sequencing supports distinct reactive oxygen species-mediated pathways of apoptosis by high and low size mass fractions of Bay leaf (Lauris nobilis) in HT-29 cells. Food Funct. 2015 6(8):2507-24
  • Tan SM, Sharma A, Stefanovic N, Yuen DY, Karagiannis TC, Meyer C, Ward KW, Cooper ME, de Haan JB. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes. 2014 Sep;63(9):3091-103
  • Tortorella SM, Royce SG, Licciardi PV, Karagiannis TC. Dietary Sulforaphane in Cancer Chemoprevention: The Role of Epigenetic Regulation and HDAC Inhibition. Antioxid Redox Signal. 2015 Jun 1;22(16):1382-424
  • Rafehi H, Balcerczyk A, Lunke S, Kaspi A, Ziemann M, Kn H, Okabe J, Khurana I, Ooi J, Khan AW, Du XJ, Chang L, Haviv I, Keating ST, Karagiannis TC, El-Osta A. Vascular histone deacetylation by pharmacological HDAC inhibition. Genome Res. 2014 Aug;24(8):1271-84